Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 17/20 | 0.71 |
| ▸ | TNF | P01375 | 1/20 | 0.66 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.66 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15528013 | 0.89 | IL2 (0.79) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL15528584 | 0.87 | IL2 (0.73) | IL2TNFSTIM1ORAI1KDR | |
| SCHEMBL15205822 | 0.86 | IL2 (0.78) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL16650120 | 0.86 | IL2 (0.71) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL15528594 | 0.86 | IL2 (0.71) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL15528662 | 0.84 | IL2 (0.69) | IL2TNFSTIM1ORAI1KDR | |
| SCHEMBL2733477 | 0.84 | IL2 (0.81) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL15205182 | 0.83 | IL2 (1.00) | IL2TNFSTIM1ORAI1 | |
| SCHEMBL2732321 | 0.83 | IL2 (0.71) | IL2TNFSTIM1ORAI1RAB9A | |
| SCHEMBL15528464 | 0.82 | IL2 (0.71) | IL2TNFSTIM1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | claimed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | claimed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | claimed |
| EP-2844655-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2015-03-11 | — | — | EP | claimed |
| WO-2013164769-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2013-11-07 | — | — | WO | claimed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-10-20 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| US-9399638-B2 | Substituted pyridine compounds as CRAC modulators | LUPIN LIMITED (IN) | 2016-07-26 | — | — | US | disclosed |
| WO-2015090579-A1 | PYRAZOLYL-BASED CARBOXAMIDES IV | Grünenthal GmbH (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | Grünenthal GmbH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111900-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | IL2 2982/4885TNF 2731/4885STIM1 29/4885 |
| US-20160304506-A1 | SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | IL2 2982/4885TNF 2731/4885STIM1 29/4885 |
| US-20150166505-A1 | PYRIDINYL-SUBSTITUTED PYRAZOLYL CARBOXAMIDES | AADAC, NLRP3, NOD2 | IL2 1229/4885TNF 517/4885STIM1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.